MG
RXST icon

Michael Gelband’s RxSight RXST Stock Holding History

Michael Gelband’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,638
Closed -$657K – 1995
2026
Q1 		$657K Buy
106,638
+15,716
+17% +$131K 0.01% 1118
2025
Q4 		$947K Buy
90,922
+23,500
+35% +$236K 0.01% 1017
2025
Q3 		$606K Buy
+67,422
New +$592K 0.01% 1129
2025
Q2 		– Sell
-15,944
Closed -$403K – 1911
2025
Q1 		$403K Sell
15,944
-8,473
-35% -$252K ﹤0.01% 1159
2024
Q4 		$839K Buy
24,417
+6,534
+37% +$295K 0.01% 1000
2024
Q3 		$884K Buy
+17,883
New +$916K 0.01% 1007
2024
Q2 		– Sell
-11,114
Closed -$573K – 1924
2024
Q1 		$573K Buy
+11,114
New +$546K ﹤0.01% 1109

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's RXST Position: Q2 2026 in Review

Michael Gelband sold out of RxSight (RXST) in Q2 2026, closing a stake of 106,638 shares — an estimated $657K sold.

Michael Gelband first reported a position in RXST in Q1 2024 and held it in 7 quarters. The position peaked at $947K in Q4 2025. 150 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Michael Gelband reported no remaining RxSight position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 106,638 RxSight shares in Q2 2026, an estimated $657K.
  • Michael Gelband first reported a position in RxSight in Q1 2024 and held it in 7 quarters.
  • Michael Gelband's RxSight position peaked at $947K in Q4 2025.
  • 150 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.